G-15: Selective GPR30 Antagonist for Estrogen Signaling Research

Executive Summary: G-15 (CAS 1161002-05-6) is a highly selective antagonist of the G protein-coupled estrogen receptor 30 (GPR30), with a binding affinity (Ki) of approximately 20 nM, and does not significantly bind to classical estrogen receptors ERα or ERβ even at high concentrations (APExBIO). It blocks estrogen- and G-1-induced intracellular calcium mobilization and PI3K/Akt pathway activation, making it a critical tool for dissecting non-genomic estrogen signaling (Wang et al. 2021). G-15 demonstrates dose-dependent inhibition of G-1-induced calcium mobilization in SKBr3 cells (IC50 ≈ 185 nM) and reverses G-1-stimulated proliferation. In vivo, G-15 impairs spatial learning in ovariectomized female rats at 5–10 μg/day SC, confirming GPR30's physiological relevance. G-15 is widely used in research on neurodegeneration, cancer, and immune modulation involving GPR30 signaling (America Peptide).

Biological Rationale

GPR30, also known as G protein-coupled estrogen receptor 1 (GPER1), is an integral membrane receptor primarily localized in the endoplasmic reticulum (Wang et al. 2021). Unlike nuclear estrogen receptors ERα and ERβ, GPR30 mediates rapid, non-genomic signaling effects of estrogens such as 17β-estradiol. Activation of GPR30 leads to intracellular calcium mobilization, PI3K pathway activation, and subsequent phosphorylation of Akt, which modulates cell proliferation and survival. These pathways are implicated in neuroprotection, immune modulation, and cancer progression. The precise inhibition of GPR30, without affecting ERα/ERβ, is critical for studying these rapid estrogenic effects in both physiological and pathological contexts. G-15, as a selective GPR30 antagonist, fills this experimental gap by enabling targeted dissection of GPR30 functions (Phosphatase Inhibitor extends this article by focusing on troubleshooting and workflow integration).

Mechanism of Action of G-15

G-15 binds selectively to GPR30 (Ki ≈ 20 nM) and blocks the receptor’s activation by endogenous ligands such as estradiol and synthetic agonists like G-1 (APExBIO). This antagonism inhibits downstream intracellular calcium mobilization, as measured in SKBr3 breast cancer cells, where G-15 shows dose-dependent inhibition of G-1-mediated calcium flux (IC50 ≈ 185 nM). G-15 also blocks GPR30-mediated activation of phosphoinositide 3-kinase (PI3K), reducing Akt phosphorylation. These effects have been validated in multiple cell lines and primary cell systems. Importantly, G-15 shows negligible activity against ERα and ERβ even at concentrations significantly above those required for GPR30 antagonism, ensuring pathway specificity (Wang et al. 2021).

Evidence & Benchmarks

• G-15 selectively inhibits GPR30-mediated calcium mobilization in SKBr3 cells (IC50 ≈ 185 nM, 37°C, HBSS buffer, 10 min incubation) (DOI).
• G-15 does not significantly interact with ERα or ERβ at concentrations up to 10 μM (competitive binding assays, in vitro) (DOI).
• In ovariectomized female rats, subcutaneous administration of G-15 at 5 or 10 μg/day impairs spatial learning acquisition (behavioral water maze, 14-day protocol) (DOI).
• G-15 reverses G-1-induced proliferation of splenic CD4+ T lymphocytes after hemorrhagic shock in ex vivo rat models (ConA stimulation, 48 h, CCK-8 assay) (DOI).
• G-15 is insoluble in water and ethanol but dissolves in DMSO at ≥37 mg/mL, enabling preparation of >10 mM stock solutions for experimental use (APExBIO).

Applications, Limits & Misconceptions

G-15 is a gold-standard tool for:

• Dissecting non-genomic estrogen signaling: By selectively inhibiting GPR30, G-15 distinguishes rapid, membrane-initiated pathways from classical nuclear ER-mediated effects (G-Protein-Coupled-Receptor.com; this article updates with new in vivo benchmarks).
• Neurobiology research: G-15 is used in models of neurodegeneration to probe GPR30’s role in cognition and neuroprotection (Wang et al. 2021).
• Cancer biology: G-15 enables the study of GPR30-driven proliferation and migration in breast and other cancers (America Peptide; this article extends to immune modulation and learning paradigms).
• Immunology: G-15 clarifies the role of GPR30 in T cell function, especially after immune challenge or injury.

Common Pitfalls or Misconceptions

• G-15 does not significantly antagonize ERα or ERβ, even at high concentrations; it is not a pan-estrogen receptor antagonist.
• G-15 is ineffective in settings where non-GPR30 estrogen signaling predominates (e.g., classical ER-driven transcriptional effects).
• Prolonged storage of G-15 solutions (>1 week) is not recommended; potency may decrease due to DMSO degradation (APExBIO).
• G-15 is insoluble in water and ethanol, requiring DMSO for stock solutions; improper solubilization can lead to precipitation and loss of activity.
• In vivo, off-target effects are rare but possible at doses far exceeding those tested for GPR30 specificity.

Workflow Integration & Parameters

For in vitro assays, G-15 is dissolved in DMSO at concentrations ≥37 mg/mL to yield stock solutions of >10 mM. Working concentrations typically range from 100 nM to 10 μM, depending on cell type and endpoint (APExBIO). Stocks should be prepared fresh or stored at -20°C for short periods; warming and ultrasonic treatment can enhance solubility. In calcium mobilization assays, preincubate cells with G-15 for 10–30 min before agonist addition. For in vivo use, subcutaneous administration at 5–10 μg/day has been shown effective in rat models. Use validated controls such as G-1 (agonist) and vehicle-only groups. For troubleshooting and advanced strategies, see this guide (this article clarifies translational immunology applications versus mechanistic cell biology).

Conclusion & Outlook

G-15 stands as a rigorously benchmarked, highly selective GPR30 antagonist enabling precision dissection of non-genomic estrogen signaling. Its robust selectivity profile and validated workflows make it indispensable for research in neurobiology, cancer, and immune modulation. As new GPR30-dependent mechanisms emerge in physiology and disease, G-15 will remain a key resource for exploration. For comprehensive protocols and supply, refer to the APExBIO G-15 product page. For strategic guidance and future directions, see this thought-leadership article (extending this dossier with strategic and translational perspectives).